Cogent Biosciences’ Two Late-Stage Assets Offer Over $3BN Peak Sales
UBS analysts named Cogent Biosciences their top SMID-cap biotech pick, citing its two late-stage assets in gastrointestinal stromal tumors and indolent systemic mastocytosis. Strong Phase III data and over $3 billion in peak sales potential underpin significant upside relative to peers.
1. Top SMID-Cap Biotech Pick
Analysts named Cogent Biosciences their top SMID-cap biotechnology pick, emphasizing the company’s scarcity value and advanced pipeline position.
2. Late-Stage Asset Data
Cogent is advancing two late-stage drug candidates with robust Phase III results in gastrointestinal stromal tumors and indolent systemic mastocytosis, underscoring clinical momentum.
3. Peak Sales Potential and Valuation Upside
The combined peak sales potential for these assets exceeds $3 billion, suggesting significant valuation upside compared with recent SMID-cap transactions such as Blueprint Medicines’ $9 billion sale.